Transcriptional mediators of blood vessel development and endothelial differentiation
CA 2436876 A1 · Owner: Beth Israel Deaconess Medical Center · Inventors: Libermann, Towia; Oettgen, Peter
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention relates to methods of modulating the development of blood vessels and/or endothelial cell differentiation in a mammal comprising altering the activity of an Ets transcription factor which activates vascular specific genes. More particularly, the transcription factor comprises ELF-1 and transcription factors that are homologous to ELF-1. The invention further relates to methods of screening for compounds that affect the development of blood vessels and/or endothelial cell differentiation. The invention also relates to methods of using these compounds to treat diseases or symptoms of , diseases, by either increasing or decreasing blood vessel development and/or …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 28, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended November 28, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 28, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.